Retinopathy of Prematurity

01Pathophysiology

Retinopathy of prematurity is a biphasic vasoproliferative disorder of the developing retina that occurs almost exclusively in preterm infants. To understand the disease, one must first understand normal retinal vascular development. Retinal vessels begin growing from the optic disc at approximately 16 weeks of gestation, reach the nasal ora serrata by 32 weeks, and complete their growth at the temporal ora serrata around 40 to 44 weeks. A premature birth interrupts this orderly process, leaving the peripheral retina incompletely vascularized at delivery.

Phase 1 is vaso-obliteration, occurring roughly from birth to postmenstrual age 30 to 32 weeks. After premature birth, the infant transitions from a relatively hypoxic in-utero environment (arterial oxygen tension around 30 mmHg) to a relatively hyperoxic extrauterine environment, often compounded by supplemental oxygen therapy. The resulting hyperoxia suppresses vascular endothelial growth factor and insulin-like growth factor 1, halting normal retinal vessel development and even causing regression of existing vessels. The result is an avascular peripheral retina.

Phase 2 is vasoproliferation, beginning around postmenstrual age 32 to 34 weeks. As the infant grows, the metabolic demand of the maturing retina rises, but the avascular periphery cannot meet that demand, creating localized retinal hypoxia. This hypoxia drives a surge in vascular endothelial growth factor and erythropoietin, triggering pathologic neovascularization at the junction between vascularized and avascular retina. These new vessels are fragile, leaky, and grow into the vitreous rather than along the retinal surface.

The resulting fibrovascular proliferation can contract over time, exerting traction on the retina and potentially causing retinal detachment, which is the principal mechanism of severe visual loss. Concurrent dilation and tortuosity of the posterior pole vessels, called "plus disease," signals active, aggressive disease and is a critical sign that mandates treatment.

A particularly aggressive form, formerly called "aggressive posterior retinopathy of prematurity" and now termed aggressive retinopathy of prematurity, occurs in the smallest, sickest infants. It progresses rapidly to retinal detachment without passing through the classical staged sequence and demands prompt intervention.

The clinical correlations follow directly from this mechanism. The disease is silent in early stages because peripheral retinal changes do not produce symptoms an infant can communicate, which is why routine screening of at-risk preterm infants is mandatory. When advanced disease manifests, traction on the macula or frank retinal detachment produces leukocoria, poor fixation, strabismus, or nystagmus, often presenting weeks to months after the neonatal intensive care unit stay.

02Classification and Clinical Manifestation

03Diagnostic Workup

The diagnostic approach to retinopathy of prematurity is fundamentally a screening problem rather than a symptom-driven workup, because the disease is asymptomatic in its treatable stages. Screening criteria broadly include infants born at gestational age 30 weeks or less, or with a birth weight of 1500 g or less, and selected larger preterm infants with an unstable clinical course as judged by the neonatologist. The first examination is timed by postmenstrual age and chronologic age: typically at 31 weeks postmenstrual age for infants born at less than 27 weeks, and at 4 weeks chronologic age for infants born at 27 weeks or later, whichever comes later.

The best initial test and the confirmatory test are the same: a thorough dilated indirect ophthalmoscopic examination with scleral depression performed by an ophthalmologist trained in retinopathy of prematurity. Pupils are dilated with cyclopentolate and phenylephrine drops. The examiner systematically documents the zone of disease, stage of disease, extent in clock hours, and the presence or absence of plus disease, applying the International Classification of Retinopathy of Prematurity. There is no laboratory test or imaging modality that replaces this examination.

Wide-field digital retinal imaging has become an important adjunct, particularly where access to specialists is limited. Captured images can be reviewed remotely by an experienced reader, enabling telemedicine-based screening. Fluorescein angiography is selectively used to delineate the avascular retina and active leakage, especially in aggressive posterior disease where landmarks are subtle. Ocular ultrasound is reserved for cases where vitreous hemorrhage or other media opacity prevents direct retinal visualization, and is particularly useful for confirming retinal detachment.

The frequency of follow-up examinations is dictated by findings: weekly or more often for zone I disease, any stage 3, or plus disease; every two weeks for less concerning findings; and screening continues until the retina is fully vascularized or the infant has clearly regressed past the threshold for treatment.

04Management and Treatment

Prevention is the foundation of management. The most testable preventive principle is judicious oxygen titration: target oxygen saturations of approximately $9090$ to $95\mathrm{\%}95\backslash \%$ in extremely preterm infants, because both excessive oxygen and prolonged hypoxia increase risk, and fluctuating saturations are particularly damaging. Optimizing nutrition and postnatal weight gain supports endogenous insulin-like growth factor 1, which is protective.

Once type 1 disease is identified, treatment must be initiated within 48 to 72 hours. The two definitive options are intravitreal anti-vascular endothelial growth factor injection and laser photocoagulation.

Anti-vascular endothelial growth factor therapy with bevacizumab at $0.6250.625$ mg per eye or ranibizumab at $0.20.2$ mg per eye is increasingly preferred, especially for zone I disease and aggressive retinopathy of prematurity, because it produces rapid regression of neovascularization and allows continued peripheral retinal vascularization. The trade-off is the risk of late recurrence, sometimes months after treatment, requiring prolonged follow-up well beyond the typical screening period. There is also theoretical concern about systemic vascular endothelial growth factor suppression in a developing infant.

Laser photocoagulation with a diode laser ablates the avascular peripheral retina, removing the source of vascular endothelial growth factor. It produces a permanent peripheral visual field defect and induces myopia but has decades of evidence supporting durable control. It remains a first-line option for zone II disease and where anti-vascular endothelial growth factor agents are unavailable.

The "next best step" logic is testable: in an infant with zone I plus disease or aggressive retinopathy of prematurity, the next best step is prompt anti-vascular endothelial growth factor injection or laser, not observation. In an infant with type 2 disease, the next best step is close observation with weekly examinations, not treatment.

When the disease has progressed to stage 4 (partial retinal detachment) or stage 5 (total detachment), vitreoretinal surgery with scleral buckling or lens-sparing vitrectomy is required. Visual outcomes in stage 5 are generally poor.

Long-term management is mandatory. Even successfully treated children remain at elevated lifetime risk for high myopia, strabismus, amblyopia, glaucoma, and late retinal detachment, requiring regular ophthalmologic follow-up throughout childhood and into adulthood.

There are no contraindications based on pregnancy or renal failure (the patient is a neonate), but systemic anti-vascular endothelial growth factor exposure is a theoretical caution in the smallest infants and is the subject of ongoing study.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss questions on retinopathy of prematurity is by failing to recognize that screening is mandatory and asymptomatic. A vignette describing a former 28-week preemie now at 36 weeks postmenstrual age does not need to mention any visual symptoms for the answer to be "schedule dilated fundus examination." Students who wait for leukocoria or strabismus to choose retinopathy of prematurity will miss the treatable window.

A second classic trap is the "oxygen paradox." Although hyperoxia drives the initial vaso-obliterative phase, the disease ultimately progresses because of hypoxia-driven vasoproliferation in phase 2. Test writers exploit this by asking why a stable infant on room air develops worsening retinopathy weeks after oxygen has been weaned, or by asking about target oxygen saturations: the correct answer is the balanced range of $9090$ to $95\mathrm{\%}95\backslash \%$, not "as low as possible" or "as high as possible."

Another high-yield gotcha is the timing of treatment. Once type 1 disease is diagnosed, treatment must occur within 48 to 72 hours, and the threshold for treatment is defined by the combination of zone, stage, and plus disease, not by stage alone. A vignette of zone I, stage 3, without plus disease still meets type 1 criteria and warrants treatment, while zone II, stage 3 without plus disease is type 2 and warrants observation. Memorizing the type 1 versus type 2 distinction is critical.

A subtler trap is the differentiation from familial exudative vitreoretinopathy and persistent fetal vasculature, both of which can mimic retinopathy of prematurity on examination. The discriminator is invariably found in the history: a term infant with peripheral avascularity and a positive family history points to familial exudative vitreoretinopathy, not retinopathy of prematurity. Retinopathy of prematurity requires prematurity by definition.

Finally, do not forget the long-term sequelae even after successful treatment: high myopia, amblyopia, strabismus, and late retinal detachment all warrant lifelong ophthalmologic follow-up. A question asking about the appropriate follow-up plan for a 5-year-old with treated retinopathy of prematurity expects "annual ophthalmologic examination," not "discharge from care."

The core competency being tested is recognizing an asymptomatic, time-sensitive, screening-detected disease in a high-risk population, sequencing the workup correctly through dilated fundus examination, and applying the zone-stage-plus framework to decide between treatment and observation.